Bionano Genomics Reports First Quarter 2021 Financial Results and Highlights Recent Business Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
BioNano Genomics, Inc. (BNGO) Reports Q1 EPS of $0.00
May 13, 2021 4:35 PM EDTBioNano Genomics, Inc. (NASDAQ: BNGO) reported Q1 revenue $3.2 million versus the consensus estimate of $2.9 million.
2021 is off to a solid start for Bionano. In the first quarter, we sold a record number of flow cells, analyzed a record number of samples in our service lab, drove broad adoption of Saphyr instruments and ramped up the installation of Saphyr systems that werent yet operational because of 2020s travel restrictions, said Erik Holmlin, PhD, CEO of Bionano. With the largest number of Saphyr systems in service... More
